Discover
ACXP
Acurx Pharmaceuticals, Inc.
1.27
2 x 0.91
2 x 1.63
bid
ask
+
0.02
1.60%
2 @ 04:00 PM
1.25 -0.02 (1.57%)
| Ytd | -49.00% | |
| 1y | -82.93% |
1.24
day range
1.28
1.25
52 week range
7.59
| Open | 1.24 | Prev Close | 1.25 | Low | 1.24 | High | 1.28 | Mkt Cap | 7.06M |
| Vol | 41.15K | Avg Vol | 125.08K | EPS | -2.73 | P/E | N/A | Forward P/E | -0.56 |
| Beta | -1.72 | Short Ratio | 12.59 | Inst. Own | 11.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 1.40 | 200-d Avg | 2.12 | 1yr Est | 11.19 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.23 | -0.17 | 0.06 | 26.09% |
| 2024-08-09 | 2024-06 | -0.28 | -0.26 | 0.02 | 7.14% |
| 2024-08-09 | 2024-06 | -0.28 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -0.24 | -0.28 | -0.04 | -16.67% |
| 2024-05-14 | 2024-03 | -0.24 | N/A | N/A | N/A |
| 2024-03-15 | 2023-12 | -0.26 | -0.38 | -0.12 | -46.15% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-02-28 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-02 | DELUCCIA ROBERT J | Director and Beneficial Owner of more than 10% of a Class of Security | 964.78K | Conversion of Exercise of derivative security |
| 2024-01-02 | LUCI DAVID P | Chief Executive Officer | 1.10M | Conversion of Exercise of derivative security |
| 2024-01-18 | SAILER CARL | Director | 117.55K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Group Inc | 529.35K | 463.18K | 3.13% |
| 2024-09-29 | Prospect Financial Services LLC | 295.08K | 258.19K | 1.75% |
| 2024-09-29 | Geode Capital Management, LLC | 146.50K | 128.19K | 0.87% |
| 2024-09-29 | LPL Financial LLC | 44.78K | 39.18K | 0.27% |
| 2024-09-29 | Morgan Stanley | 46.20K | 40.42K | 0.27% |
| 2024-09-29 | State Street Corporation | 43.47K | 38.03K | 0.26% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 383.81K | 335.84K | 2.27% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 145.54K | 127.34K | 0.86% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 77.31K | 67.65K | 0.46% |
| 2024-10-30 | iShares Micro Cap ETF | 24.88K | 21.77K | 0.15% |
| 2024-10-30 | Fidelity Total Market Index Fund | 20.03K | 17.53K | 0.12% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 18.30K | 16.01K | 0.11% |
Split
| Split | Date |
|---|---|
| 1 : 20 | 2025-08-05 |